By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion said today that its revenues rose to $431,000 in the first quarter, compared to $73,000 in Q1 2010, as more than 3,000 of its OVA1 ovarian cancer tests were performed.

The firm's results fell short of analysts' expectations of $520,000 in revenues.

For the three months ended March 31, product revenues came in at $317,000, compared to none a year ago, and licensing revenues were $114,000, up from $73,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.